WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations
WuXi Biologics has been awarded the 2023 ISPE Facility of the Year Award (FOYA) in the Operations category for its manufacturing facility in Dundalk, Ireland. The facility, one of the largest of its kind in Europe, features two manufacturing areas with 6x1KL single-use bioreactors for perfusion and 12x4KL single-use bioreactors for fed-batch. Construction of the 467,500-square-foot greenfield facility began in December 2018 and operations started in December 2021, creating over 6,000 construction jobs and more than 500 highly skilled jobs in the region.
The facility received its first GMP certificate from the Irish Health Products Regulatory Authority (HPRA) just nine months after starting operations. In line with WuXi Biologics' ESG strategy, the site incorporates sustainable concepts, including 100% renewable energy power supply. This marks the second FOYA recognition for WuXi Biologics, following an Honorable Mention in 2014 for its facility in Wuxi city, China.
WuXi Biologics ha ricevuto il premio 2023 ISPE Facility of the Year Award (FOYA) nella categoria Operazioni per il suo impianto di produzione a Dundalk, Irlanda. L'impianto, uno dei più grandi del suo genere in Europa, dispone di due aree di produzione con bioreattori monouso da 6x1KL per la perfusione e bioreattori monouso da 12x4KL per il metodo a lotti alimentati. La costruzione della struttura greenfield di 467.500 piedi quadrati è iniziata nel dicembre 2018 e le operazioni sono iniziate nel dicembre 2021, creando oltre 6.000 posti di lavoro nella costruzione e più di 500 posti di lavoro altamente qualificati nella regione.
L'impianto ha ricevuto il suo primo certificato GMP dall'Irish Health Products Regulatory Authority (HPRA) solo nove mesi dopo l'inizio delle operazioni. In linea con la strategia ESG di WuXi Biologics, il sito incorpora concetti sostenibili, compreso un approvvigionamento energetico 100% rinnovabile. Questo rappresenta il secondo riconoscimento FOYA per WuXi Biologics, dopo una menzione d'onore nel 2014 per il suo impianto nella città di Wuxi, in Cina.
WuXi Biologics ha sido galardonada con el Premio ISPE Facility of the Year 2023 (FOYA) en la categoría de Operaciones por su instalación de fabricación en Dundalk, Irlanda. La instalación, una de las más grandes de su tipo en Europa, cuenta con dos áreas de fabricación que disponen de biorreactores desechables de 6x1KL para perfusión y biorreactores desechables de 12x4KL para procesos de alimentación por lotes. La construcción de esta instalación de 467,500 pies cuadrados comenzó en diciembre de 2018 y las operaciones iniciaron en diciembre de 2021, generando más de 6,000 puestos de trabajo en la construcción y más de 500 empleos altamente cualificados en la región.
La instalación recibió su primer certificado GMP de la Autoridad Reguladora de Productos de Salud de Irlanda (HPRA) solo nueve meses después de comenzar sus operaciones. En línea con la estrategia ESG de WuXi Biologics, el sitio incorpora conceptos sostenibles, incluida una fuente de energía 100% renovable. Este es el segundo reconocimiento FOYA para WuXi Biologics, después de una mención honorífica en 2014 por su instalación en la ciudad de Wuxi, China.
우시 바이오로직스(WuXi Biologics)는 2023 ISPE 올해의 시설상 (FOYA) 운영 부문에서 아일랜드 던들크에 있는 제조 시설로 수상했습니다. 이 시설은 유럽에서 가장 큰 종류 중 하나로, 단일 사용 바이오리액터 6x1KL 2개와 공급 배치용 단일 사용 바이오리액터 12x4KL 12개로 구성된 두 개의 제조 구역을 특징으로 합니다. 467,500 평방 피트 규모의 녹지 개발 시설은 2018년 12월에 착공되어 2021년 12월에 운영을 시작하였으며, 6,000개 이상의 건설 일자리와 500개 이상의 고숙련 일자리를 창출했습니다.
이 시설은 운영 시작 9개월 만에 아일랜드 보건 제품 규제 기관(HPRA)으로부터 첫 번째 GMP 인증을 받았습니다. 우시 바이오로직스의 ESG 전략에 따라 이 현장은 100% 재생 가능 에너지 공급을 포함한 지속 가능한 개념을 통합하고 있습니다. 이는 2014년 중국 우시시 시설에 대한 특별 언급에 이어 우시 바이오로직스의 두 번째 FOYA 인정입니다.
wuxi biologics a reçu le prix ISPE Facility of the Year 2023 (FOYA) dans la catégorie des opérations pour son installation de fabrication à Dundalk, Irlande. Cette installation, l'une des plus grandes de son genre en Europe, comprend deux zones de fabrication avec des bioréacteurs jetables de 6x1KL pour perfusion et 12x4KL pour les lots alimentés. La construction de cette installation de 467,500 pieds carrés a commencé en décembre 2018 et les opérations ont débuté en décembre 2021, créant plus de 6,000 emplois dans la construction et plus de 500 emplois hautement qualifiés dans la région.
L'installation a reçu son premier certificat GMP de l'Autorité Régulatrice des Produits de Santé Irlandaise (HPRA) seulement neuf mois après le début de ses opérations. En ligne avec la stratégie ESG de WuXi Biologics, le site intègre des concepts durables, y compris une alimentation en énergie 100 % renouvelable. Cela marque la deuxième reconnaissance FOYA pour WuXi Biologics, après une mention honorable en 2014 pour son installation dans la ville de Wuxi, en Chine.
WuXi Biologics wurde mit dem 2023 ISPE Facility of the Year Award (FOYA) in der Kategorie Betrieb für seine Produktionsstätte in Dundalk, Irland ausgezeichnet. Die Einrichtung, eine der größten ihrer Art in Europa, verfügt über zwei Produktionsbereiche mit 6x1KL Einweg-Bioreaktoren für Perfusion und 12x4KL Einweg-Bioreaktoren für die Chargenversorgung. Der Bau der 467.500 Quadratfuß großen Greenfield-Anlage begann im Dezember 2018, und die Betriebsaufnahme erfolgte im Dezember 2021, was über 6.000 Bauarbeitsplätze und mehr als 500 hochqualifizierte Arbeitsplätze in der Region schuf.
Die Einrichtung erhielt ihr erstes GMP-Zertifikat von der irischen Gesundheitsprodukte-Behörde (HPRA) nur neun Monate nach Beginn der Betrieb. Im Einklang mit der ESG-Strategie von WuXi Biologics integriert der Standort nachhaltige Konzepte, einschließlich einer 100% erneuerbaren Energieversorgung. Dies ist die zweite FOYA-Auszeichnung für WuXi Biologics, nach einer ehrenvollen Erwähnung im Jahr 2014 für ihre Anlage in der Stadt Wuxi, China.
- Received 2023 ISPE Facility of the Year Award in Operations category
- One of the largest facilities of its kind in Europe
- Created over 6,000 construction jobs and 500 highly skilled jobs
- Obtained GMP certificate within 9 months of starting operations
- 100% renewable energy power supply at Ireland site
- None.
DUNDALK,
The awarded facility includes two manufacturing areas utilizing 6x1KL single-use bioreactors for perfusion and 12x4KL single-use bioreactors for fed-batch, making it one of the largest facilities of its kind in
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very proud to be recognized by ISPE for the second time. Receiving the FOYA award in the Operations category validates our Global Dual Sourcing strategy, leading technology platform, and excellent execution, and will motivate us to continue striving for the highest level of service to enable our global partners for the benefit of patients worldwide."
Brendan McGrath, Vice President and Head of WuXi Biologics Ireland Site, added, "This recognition by ISPE is a testament to our team's dedication and relentless pursuit of excellence. It also signifies success for our clients, partners and local community, and ultimately for the patients who rely on the life-saving biologics manufactured at our
In 2014, WuXi Biologics was awarded the FOYA Honorable Mention for its manufacturing facility in
About the ISPE Facility of the Year Awards Program
Established in 2005, The Facility of the Year Awards (FOYA) recognize state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operation, while sharing the development of new applications of technology and cutting-edge approaches. Visit ISPE.org/FOYA for more information.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-biologics-receives-2023-ispe-facility-of-the-year-award-for-operations-301830506.html
SOURCE WuXi Biologics
FAQ
What award did WuXi Biologics (WXXWY) receive in 2023?
How many jobs did WuXi Biologics (WXXWY) create with its Dundalk facility?
When did WuXi Biologics (WXXWY) start operations at its Dundalk facility?
What percentage of power supply comes from renewable energy at WuXi Biologics' (WXXWY) Ireland site?
